Takeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502):
Strong first half results led by Growth Drivers
Underlying Revenue grew +7.4%, led by a +15.3% increase of Takeda's
(GI, Oncology, CNS and Emerging Markets). Reported revenue declined -5.9%, due to unfavorable currencies (-8.6pt) and the impact of divestitures (-4.7pt).
- Underlying Core Earnings advanced +12.7% with the Core Earnings margin increasing by 0.7pt. Despite unfavorable currencies and the negative impact of divestitures, reported operating profit was up +46.7% benefiting from strong underlying growth and a one-time gain on the Teva JV transaction.
- Underlying Core EPS was up +49.3%, reflecting strong Core Earnings growth and a lower tax rate due to timing. Reported EPS more than doubled to 159 yen, up from 69 yen in the prior year period.
- Reported Operating Free Cash Flow was up 34.0% to 74.6 billion yen driven by continued working capital improvements.
Takeda's Growth Drivers delivered 15.3% Revenue growth
- GI underlying revenue grew +39.4%, driven by ENTYVIO® and TAKECAB®.
- Oncology underlying revenue grew +4.9% driven by NINLARO® and ADCETRIS®.
- CNS underlying revenue of +28.2% was boosted by a strong TRINTELLIX® performance.
- Emerging Markets underlying revenue growth was +4.9% with Q2 growth accelerating to +5.7%.
Underlying Revenue growth across all regions, led by continued double-digit performance in the US
- Japan underlying revenue was up +4.1%, driven by TAKECAB®, AZILVA® and LOTRIGA®.
- US underlying revenue growth of +15.1%, led by ENTYVIO®, NINLARO® and TRINTELLIX®.
- Europe and Canada underlying revenue grew +4.8%, driven by ENTYVIO® and ADCETRIS®.
- Emerging Markets underlying revenue was up +4.9%, with robust growth in the key markets of Brazil (+11.1%), China (+9.7%) and Russia (+8.4%).
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"Today we reported strong first half results in a year of significant
transformation. This strong momentum allows us to increase our full year
The recent positive CHMP opinion for the conditional approval of NINLARO ® in the EU was an important step to bring this new treatment option to patients worldwide. I am confident that our Growth Drivers will continue to fuel our momentum well into the future."
Reported Results for H1 (April – September) of FY2016
|EPS||69 yen||159 yen||+129.4%||N/A|
|Core EPS||138 yen||139 yen||+1.2%||+49.3%|
|Core Earnings is calculated by taking reported gross profit and deducting SG&A expenses and R&D expenses.|
|In addition, certain other items that are non-core in nature and significant in value may also be adjusted.|
|Underlying growth compares two periods of financial results under a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures.|
|Attributable to the owners of the company.|
Takeda increases management guidance for Underlying Core Earnings to "mid- to high-teen growth" and Underlying Core EPS is trending to the high end of the "low- to mid-teen growth" range
FY2016 Management Guidance
(May 10, 2016)
(Oct 28, 2016)
|Underlying Revenue||Mid single digit growth (%)||Mid single digit growth (%)|
|Underlying Core Earnings||Low- to mid-teen growth (%)||Mid- to high-teen growth (%)|
|Underlying Core EPS||Low- to mid-teen growth (%)||Low- to mid-teen growth (%)|
|Annual Dividend per Share||180 yen||180 yen|
Reported Net Profit/EPS forecast increased despite accelerated R&D transformation costs and unfavorable currency impact
Total estimated costs related to the R&D transformation program are unchanged at 75 billion yen; with 40 billion yen estimated in FY2016 (previous forecast was 25 billion yen) and 35 billion yen in FY2017.
FY2016 Reported Forecast
(May 10, 2016)
(Oct 28, 2016)
|Net Profit 3||88.0||91.0|
|EPS||112 yen||116 yen|
|Exchange Rate (annual average)||1 US$=110 yen, 1 euro=125 yen||1 US$=104 yen, 1 euro=117 yen|
|1||Includes unfavorable currency impact of approximately 68 billion yen|
|2||Includes favorable currency impact of approximately 14 billion yen|
|3||Attributable to the owners of the company|
For more details on Takeda’s FY2016 H1 results and other financial information please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom